Video

Dr. Morris on Findings From the TheraP Study in mCRPC

Michael J. Morris, MD, discusses findings from the phase 2 TheraP study, and how they led to the development of the phase 3 VISION trial in metastatic castration-resistant prostate cancer.

Michael J. Morris, MD, medical oncologist, section head, Prostate Cancer, GU Oncology, Memorial Sloan Kettering Cancer Center, discusses findings from the phase 2 TheraP study (NCT03392428), and how they led to the development of the phase 3 VISION trial (NCT03511664) in metastatic castration-resistant prostate cancer (mCRPC).

The TheraP study was the first randomized trial to evaluate the potential anticancer activity of Lutetium 177 (177Lu) PSMA-617 (177Lu-PSMA-617) vs cabazitaxel (Jevtana) in men with mCRPC, Morris says. The study did not include overall survival ​(OS) as the primary end point, but rather prostate-specific antigen (PSA) response rate, Morris says. The study demonstrated that 177Lu-PSMA-617 resulted in a higher PSA response rate compared with cabazitaxel in the second-line setting for this patient population, Morris explains. 

The results of the TheraP trial led to the development of the VISION trial because TheraP did not set OS as a clinical end point, Morris continues. Therefore, VISION moved 177Lu-PSMA-617 further in development by demonstrating OS and progression-free survival improvement with the radiopharmaceutical compared with standard of care in men with mCRPC, Morris concluded.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS